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Background. 1,3-beta-D Glucan (BDG) assay has good accuracy for distinguishing patients with invasive fungal infections 
from patients without. Some procedures and medications affect BDG levels, resulting in false-positive BDG results. The extent of 
intestinal surgery on BDG kinetics is unknown. We evaluated the influence of laparoscopic and open intestinal surgery on peri- and 
postsurgical serum BDG values.
Methods. BDG was determined in 346 samples from 50 patients undergoing laparoscopic (24) or open (26) intestinal surgery at 
the following time points: after insertion of arterial but before skin incision, after skin incision but before dissection of the intestinal 
mucosa, after completion of anastomosis, after completion of skin sutures, in the evening after surgery, day 2 after surgery, 4–5 days 
after surgery.
Results. BDG was positive (ie, concentration ≥80 pg/mL) in 54% to 61% of patients during laparoscopic and open surgery 
(highest rates after completion of skin sutures). BDG was still positive in 12% (open) to 17% (laparoscopic) of patients without any 
suspected or proven fungal infection or anastomotic leakage 4–5 days after surgery. After completion of gut anastomosis, the BDG 
increase was higher in open compared with laparoscopic intestinal surgery.
Conclusions. The value of positive BDG tests in the perioperative setting up to 5 days postsurgery seems to be limited due to 
BDG elevations from intestinal surgical procedures.
Keywords. 1,3-ß-D-Glucan; surgery; Candida.
 
Invasive candidiasis (IC) is the most common serious fungal 
infection in patients being cared for in the intensive care unit 
(ICU) [1]. Surgical ICU patients, mainly those undergoing pro-
cedures involving the gastrointestinal tract, have an increased 
risk of developing IC [2, 3]. Determination of 1,3-beta-D Glucan 
(BDG) is useful to differentiate Candida colonization from 
invasive candidiasis due to the high negative predictive value of 
this nearly “panfungal” antigen test [4–8]. Unfortunately, other 
glucans may interfere with BDG testing due to the close chem-
ical structure of, for example, cellulose (1,4-beta-D Glucan) 
with fungal BDG. False-positive results have been linked to the 
use of cellulose-containing hemodialysis membranes, blood 
derivatives, broad-spectrum antibiotics, gram-positive and 
gram-negative bacteremia, severe mucositis, and surgery, espe-
cially with involvement of the intestinal tract [9–15]. The issue 
of BDG introduction into the bloodstream and its kinetics after 
intestinal mucosal damage (eg, in mucositis or gut surgery) is 
still poorly understood. Previously, 12%–57% of surgical ICU 
patients had high BDG values without any evidence of infection 
[11, 16]. It was speculated whether the following led to elevated 
BDG levels: iatrogenic causes such as translocation, leakage, or 
leaching; introduction of BDG into the bloodstream by using 
surgical gauze, performing transfusions, or hemodialysis; or 
administration of certain drugs [11]. Although leakage of the 
gut and subsequent translocation of fungal elements into the 
bloodstream have been shown to be a likely cause of increased 
blood BDG levels in patients with HIV infection [17], our study 
group has shown that mild to moderate chemotherapy-induced 
mucosal barrier damage is not associated with elevated blood 
BDG levels [18]. Recently, we also demonstrated that BDG 
testing is reliable in patients undergoing hemodialysis and that 
modern dialysis membranes do not release BDG [19].
As life-threatening intraabdominal candidiasis occurs in 30% 
to 40% of high-risk abdominal surgical ICU patients, it is of the 
utmost importance to obtain reliable BDG values for diagno-
sis or exclusion of invasive candidiasis in this patient cohort 
[16]. However, the potential introduction of BDG from surgical 
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sponges or gauze and mucosal damage due to surgical impair-
ment of mucosal integrity are key concerns when interpreting 
elevated blood BDG levels in the context of Candida infections 
after intestinal surgery. Compared with open intestinal sur-
gery, sponges and gauze are less frequently used in laparoscopic 
intestinal surgery.
The aim of this study was to evaluate the influence of lapa-
roscopic and open intestinal surgery on peri- and postsurgical 
serum BDG values.
METHODS
In this prospective study, all patients undergoing laparoscopic or 
open intestinal surgery involving the small bowel and/or colon 
and/or rectum at the Hospital of St. John of God (Barmherzige 
Brüder), Graz, Austria, between April and June 2018 were 
asked to participate in the study and included after they 
provided informed consent. Open and laparoscopic surgical 
procedures were performed as applied in clinical routine and 
published previously [20, 21]. Assignment to 1 of the groups 
was performed by the surgeons according to the underlying 
disease and technical aspects. Laparoscopic procedures were 
performed as reduced-port surgery using a multiport system 
(OCTOtmPORT) at the umbilical incision site and 1 additional 
trocart (12-mm diameter) in the right lower abdomen. An 
electric endoscopic stapling device (SIGNIA Stapling Device) 
was used for dividing/cutting the colon or rectum in the 
laparoscopic group. In open procedures, a mechanical stapling 
device (Contour Curved Cutter Stapler) was used to cut/divide 
the colon or rectum. In both groups, an electrothermal bipolar 
sealing device (LIGASUREtm) was used to dissect and seal 
tissue or vessels and to reduce blood loss [22]. Patients were 
not eligible for the study in case of (a) ongoing antifungal 
therapy for treatment of active fungal infection or antifungal 
therapy within 4 weeks before inclusion; (b) ongoing antibiotic 
therapy before surgery other than single-shot surgical 
prophylaxis; (c) treatment of bacteremia (eg, due to Enterococcus 
sp.) within 4 weeks before inclusion; (d) clinical, radiological, 
or laboratory evidence of current infectious disease as 
assessed by the treating physician; (e) administration of 
immunoglobulin, blood, or blood products (ie, thrombocytes, 
fresh frozen plasma) within 4 weeks before inclusion; (f) 
intestinal or other abdominal surgery (laparoscopic or open) 
or other major surgeries (eg, aortocoronary bypass) within 4 
weeks before inclusion; (g) subsequent invasive candidiasis 
(defined according to proposed EORTC/MSG definitions 
of fungal infections in the ICU); or (h) other complicating 
infections occurring within 5 days after surgery. The complete 
observation period was 30  days after surgery for assessment 
of outcome and other parameters, for example, intrahospital 
or extrahospital death, necessity of antibiotic or antimycotic 
therapy due to complicating infectious disease, occurrence of 
anastomotic leakage, and subsequent surgical procedures.
Blood samples used for determination of BDG values were 
obtained at 7 scheduled time points as outlined below through 
arterial lines inserted just before sampling as a routine part of the 
anesthesia procedure: (1) 1 blood sample before intubation and 
before skin incision by the surgeon, (2) after skin incision but 
before dissection of intestinal mucosa (both samples were used 
for determination of BDG values prior to dissection of intestinal 
mucosa and possible influence of certain factors on BDG values, 
eg, insertion of vascular lines, single shot antibiotic prophylaxis, 
damaged mucosa in cancer or surgical preparation of intestine/
colon for resection of cancer), (3) after completion of anasto-
mosis, (4) after completion of skin sutures, (5) in the evening 
after surgery (ie, approximately 5–8 hours after surgery), (6) in 
the morning of day 2 after surgery (ie, approximately 18 hours 
after surgery), and (7) in the morning 4–5 days after surgery as 
part of a routine blood sampling procedure. The day of surgery 
was designated as day 1. Thus, 7 samples of 5 mL of whole blood 
were drawn in each patient using the S-Monovette collection 
system (Sarstedt, Nümbrecht, Germany). In case of signs and/
or symptoms suggestive of candidemia and/or bacteremia and/
or intraabdominal infection and/or other infectious compli-
cations, routine diagnostics were applied, for example, blood 
cultures and/or microbiological investigation of abdominal 
drainage fluids, as well as imaging studies as indicated by the 
treating physician. The serum BDG test was performed accord-
ing to recently described methods using material from the 
Fungitell Assay (Associates of Cape Cod, Falmouth, MA) [4]. 
According to the manufacturer, a BDG concentration of ≥80 
pg/mL was considered positive, whereas a concentration of <60 
pg/mL was considered negative. Concentrations <80 pg/mL but 
≥60 pg/mL were considered indeterminate, and <15.36 pg/mL 
was considered 0 pg/mL [19]. Statistical analysis was performed 
using R 3.1.1 (www.r-project.org) and SPSS Statistics 23. A P 
value of <.05 was considered statistically significant. The study 
protocol was approved by the ethics committee of the Medical 
University of Graz (nr 30–043 ex 17/18) and Hospital of St. John 
of God (Barmherzige Brüder), Graz, Austria. The study was 
registered at ClinicalTrials.gov (ClinicalTrials.gov Identifier: 
NCT03468803).
RESULTS
Baseline Demographics and BDG levels
Fifty patients were included in the study; 24 underwent lapa-
roscopic and 26 open intestinal surgery. Demographic data, 
underlying diseases, and perisurgical interventions are shown 
in Table 1. Four of 350 samples could not be assigned to sched-
uled sampling dates and were not further analyzed. Thus, 
BDG tests were performed in 346 samples from 50 patients 
(2 samples from time point 5 and 2 samples from time point 
7 were missing in 2 patients). There was no statistical differ-
ence between patients with elevated and nonelevated BDG with 
regard to observed demographic or clinical parameters (eg, sex, 
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underlying diseases, type of antibiotic prophylaxis) except age 
(Table 1). None of the patients had renal replacement therapy 
before or after surgery; received immunoglobulins, red blood 
cells or other blood products; developed invasive candidiasis; or 
received systemic antimycotic treatment. All patients survived 
the observation period of 30 days.
In the initial serum sample before skin incision, 6 of 50 
patients (12%) had positive BDG values (3 patients were under-
going laparoscopic surgery and 3 open surgery). Five of these 6 
patients had carcinoma of the colon or rectum, and 1 had non-
malignant tubulovilleous adenoma of the rectum. All 6 patients 
with initial BDG values ≥80 pg/mL had received single-shot 
antibiotic prophylaxis (5 received cefuroxime plus metronida-
zole, and 1 received ciprofloxacin plus metronidazole) before 
sampling for BDG determination. Eleven of 50 (22%) patients 
had postoperative antibiotic therapy as indicated by the treating 
physician. Two out of 7 patients with positive BDG values ≥80 
pg/mL at sampling 4–5 days after surgery had antibiotic ther-
apy, whereas 9 patients with antibiotic therapy at this time point 
had negative BDG levels. No patient developed fever within 
5 days after surgery. Three patients underwent second surgery 
due to clinically suspected anastomotic leakage, peritonitis, and 
postsurgical intestinal bleeding. After the second surgery, BDG 
rose to values ≥80 pg/mL in 2 of 3 patients.
Dynamics of BDG Levels During and After Surgery
Boxplots and medians of BDG levels at all 7 sampling time 
points are displayed in Figure  1 and Table  2. BDG values of 
all patients are shown in Figure  2. The overall proportion of 
patients with BDG values ≥80 pg/mL and absolute serum BDG 
values increased significantly after skin incision, reaching its 
peak after completion of skin sutures (29/50 patients, 58%; 
median [interquartile range], 97 [33–136] pg/mL; P  <  .001). 
Thereafter, proportions of patients with BDG values ≥80 pg/mL 
decreased, but—when compared with baseline—remained ele-
vated until (and including) the morning of day 2 after surgery.
Differences in Dynamics of BDG Levels Between Laparoscopic and Open 
Surgery
Overall, the dynamics were similar in both groups. Significant 
differences for changes of BDG values were found for compar-
ing the time point after completion of intestinal anastomosis 
with the time point after preparation of the intestine and just 
before dissection of the intestinal mucosa, with significantly 
higher increases in the open surgery group (P = .001). No dif-
ferences between those groups were found when comparing 
other time points.
DISCUSSION
In our study, laparoscopic and open intestinal surgery led to 
elevated BDG values. In comparison with previous studies, we 
investigated BDG values in the perisurgical time frame to assess 
the immediate effect of intestinal surgery. Previously, BDG val-
ues were determined in patients after 48 hours of ICU treatment 
with an expected additional stay of at least 3 days [11]. No infor-
mation could therefore be derived from the time frame during 
or immediately after surgery from that study. Nevertheless, the 
authors found a high frequency of positive BDG values early after 
ICU admission and a subsequent BDG decrease. Nine out of 35 
patients (26%) without any evidence of invasive candidiasis had 
Table 1. Demographic Data of Both Patient Groups
Laparoscopic surgery Open surgery P Value
No. 24 26
Female sex, No. (%) 7 (29.3) 13 (50) .133
Age, median (range), y 68.32 (35.73–85.78) 75.8 (56.08–91.56) .008
BMI, median (range), kg/m2 25.6 (19.26–32.39) 26.87 (19.93–37.28) .225
Underlying disease, No. (%)
 Colonic carcinoma 12 (50.0) 13 (52.0) 1.000
 Rectal carcinoma 4 (16.7) 8 (30.8) .243
 Diverticultis 5 (20.8) 3 (11.5) .370
 Other 3 (12.5) 2 (7.7) .571
Endoscopic preoperative ink  
tattooing, No. (%)
13 (54.2) 7 (26.9) .490
Second intestinal surgery, No. (%) 1 (4.2) 3 (11.5) .337
Neoadjuvant chemotherapy, No. (%) 1 (4.2) 1 (3.8) .954
Leukocytes, median (range), G/L 7.110 (4.900–7.940, n = 11) 6.950 (5.215–9.975, n = 17) .404
CRP, median (range), mg/dL 0.2 (0.1–0.3, n = 10) 0.4 (0.13–2.47, n = 16) .077
Antibiotic prophylaxis, No. (%) 24/24 (100) 26/26 (100) 1.000
Antibiotic treatment, No. (%)
 Day 2 (sample 6) 4/24 (16.7) 4/26 (15.4) .902
 4–5 d after surgery (sample 7) 5/24 (20.8) 6/26 (23.1) .848
Abbreviations: BMI, body mass index; CRP, C-reactive protein.
Bold value indicates significant difference in age.
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Table 2. P Values for Differences in Proportions of All Patients With Elevated Serum BDG Values ≥80 pg/mL at Given Sampling Time Points Respective 
to Intestinal Surgery Time Points
Proportions of 
Patients With  
BDG Values ≥80 
pg/mLa
1, Before 
Intubation,  
Before Skin 
Incision
2, Just Before 
Dissection 
of Intestinal 
Mucosa
3, After  
Completion  
of Anastomosis
4, After 
Completion  
of Skin 
Sutures
5, Evening 
After  
Surgeryb
6, Morning  
of Day 2  
After  
Surgery
7, Morning 
4–5 Days After 
Surgeryb
Proportions of patients with 
BDG values ≥80 pg/mLa
- 6/50 (12%) 15/50 (30%) 27/50 (54%) 29/50 (58%) 23/48 (48%) 19/50 (38%) 7/48 (15%)
1, before intubation, before 
skin incision
6/50 (12%) - .012 <.001 <.001 <.001 .001 1.000
2, just before dissection of 
intestinal mucosa
15/50 (30%) - - <.001 .001 .057 .424 .167
3, after completion of 
anastomosis
27/50 (54%) - - - .687 .581 .057 .001
4, after completion of skin 
sutures
29/50 (58%) - - - - .180 .013 <.001
5, evening after surgeryb 23/48 (48%) - - - - - .219 .003
6, morning of day 2 after 
surgery
19/50 (38%) - - - - - - .031
P values were calculated by McNemar test. Bold values are significant.
Abbreviation: BDG, 1,3-beta-D Glucan.
a≥80 pg/mL, ie, positive BDG values according to the manufacturer. 
bTwo samples each are missing at sample time points 5 and 7.
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Figure 1. Boxplots and medians of 1,3-beta-D Glucan (BDG) levels at all 7 sampling time points in patients undergoing laparoscopic (light gray boxplots and lines) or open 
intestinal surgery (dark gray boxplots and lines). The gray band indicates the indeterminate zone of BDG values between 60 and 80 pg/mL. BDG values above 80 pg/mL are 
positive according to the instructions of the manufacturer. BDG values below 60 pg/mL are negative.
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elevated BDG. In 8 of these patients, BDG decreased without anti-
fungal therapy, raising the assumption that elevated BDG values 
might have been an effect of surgery. It was speculated whether 
elevated BDG was a result from the surgical intervention itself, 
medical treatment, or true postsurgical invasive candidiasis [11].
Our study found that intestinal surgery led to positive BDG 
values during surgery in 54% (laparoscopic surgery) to 62% 
(open surgery) of patients. Although we focused on the time 
frame of surgery starting with sampling after insertion of arter-
ial lines for routine anesthesia until 5  days after surgery, we 
were not able to establish a direct causal relationship of certain 
underlying diseases, perisurgical interventions/procedures, 
and medications with elevated BDG values. Several procedures 
known to cause elevated BDG were applied during routine 
intestinal surgery, that is, antibiotic prophylaxis, use of gauze, 
and disintegration of intestinal mucosa. Different amounts of 
gauze are used in laparoscopic compared with open intestinal 
surgery. Considering that BDG levels tended to increase more 
during open surgery (ie, after completion of intestinal anasto-
mosis), we assume that specific interventions in open surgery 
(eg, greater use of cellulose-based gauze, greater skin incision 
compared with laparoscopic surgery) might in part be respon-
sible for elevation of BDG. However, BDG increased very early 
after preparation of the intestine and just before dissection of 
the intestinal mucosa both in laparoscopic and open surgery, 
indicating that cellulose-based gauze and skin trauma could not 
solely be responsible for elevation of BDG. As 12% of patients 
had BDG values ≥80 pg/mL before administration of periop-
erative antibiotic prophylaxis, intubation, abdominal skin dis-
infection, dressing, and skin incision, the underlying disease 
might have contributed to elevated BDG. However, as noted 
above, we found no causal relationship between underlying dis-
ease, stage of underlying disease, or demographic factors and 
elevated BDG. Whether placement of arterial lines (which was 
done before the first blood draw used for BDG testing) after 
skin disinfection using isopropanol- or octenidin-soaked gauze 
increased BDG remains unclear. As every patient received 
arterial lines but not every patient showed elevated BDG, it is 
unlikely that insertion of arterial lines led to positive BDGs. 
Other reasons previously suggested to cause elevated BDG were 
not used or were not present in our cohort, that is, administra-
tion blood products or immunoglobulins, bacterial infections 
(eg, bacteremia) before surgery, or invasive fungal infec-
tion. None of the patients received renal replacement therapy 
(RRT). In addition, we previously demonstrated that RRT using 
modern filters does not lead to elevated BDG [19]. Antibiotic 
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Figure 2. 1,3-beta-D Glucan (BDG) values of all patients undergoing laparoscopic (light gray lines) or open intestinal surgery (dark gray lines). Medians are highlighted in 
bold. The gray band indicates the indeterminate zone of BDG values between 60 and 80 pg/mL. BDG values above 80 pg/mL are positive according to the instructions of the 
manufacturer. BDG values below 60 pg/mL are negative.
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prophylaxis, administered between sampling after skin incision 
but before dissection of intestinal mucosa, might be responsible 
for the BDG increase detected at the sampling time point before 
dissection of intestinal mucosa, together with skin incision and 
use of gauze in this procedure. However, although antibiotic 
prophylaxis was applied to all patients, BDG did not increase 
in all subjects. Overall, 56% (26/50) had negative BDG values 
(<60 pg/mL) at the time point after skin incision but before dis-
section of intestinal mucosa, and the rate was still 24% (12/50) 
at the time point after completion of anastomosis. Additionally, 
9 of 11 patients with antibiotic therapy at time points 4–5 days 
after surgery had negative BDGs, indicating that administra-
tion of antibiotics is not associated with elevated BDG values in 
all patients. Overall, we were not able to associate the observed 
BDG increase with 1 particular standalone cause.
In summary, in patients undergoing intestinal surgery, pos-
itive BDG values have to be interpreted with great caution as 
surgical procedures increase BDG values. BDG reached con-
centrations ≥80 pg/mL in 54% to 61% of patients during laparo-
scopic and open surgery. BDG was still positive in 12% (open) 
to 17% (laparoscopic) of patients without any suspected or 
proven fungal infection or anastomotic leakage 4–5 days after 
surgery. Previously, BDG testing showed a high negative predic-
tive value (99%) but a weak positive predictive value (72%) for 
detection of candidemia in the ICU setting, including patients 
undergoing surgery [23]. Our study adds data to the fact that 
BDG testing might be false positive due to surgical interven-
tions, especially during and in the first days after intestinal sur-
gery. We suggest that clinicians primarily rely on negative BDG 
tests in clinical workup of patients with a short history of up to 
5 days after intestinal surgery and suspicion of fungal infection. 
The high negative predictive value of BDG testing will support 
subsequent therapeutic decisions [8]. The value of positive BDG 
tests in the perioperative setting up to 5 days after surgery seems 
to be limited due to BDG elevations by intestinal surgical proce-
dures. Health care providers must have knowledge on the utility 
of the BDG testing and factors influencing test results to avoid 
unnecessary testing and unnecessary initiation of antifungal 
treatment in case of false-positive results [24].
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